RK-682

• UNSPSC Description:

  RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24[1][2][3].

• Target Antigen:

  Autophagy; ERK; HIV Protease; Phosphatase; Phospholipase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Autophagy;MAPK/ERK Pathway;Metabolic Enzyme/Protease;Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/rk-682.html

• Smiles:

  CCCCCCCCCCCCCCCC(C1=C([C@@H](CO)OC1=O)O)=O

• Molecular Weight:

  368.51

• References & Citations:

  [1]Usui T, et al., Design and synthesis of a dimeric derivative of RK-682 with increased inhibitory activity against VHR, a dual-specificity ERK phosphatase: implications for the molecular mechanism of the inhibition. Chem Biol. 2001 Dec;8(12):1209-20.|[2]Hamaguchi T, et al., RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett. 1995 Sep 18;372(1):54-8. |[3]Tatsumi Y, et al., Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells. Int J Mol Sci. 2020 May 27;21(11):3789.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  150627-37-5